Immunome (IMNM) Current Leases (2019 - 2024)
Immunome (IMNM) reported Current Leases of $63000.0 for Q4 2024, down 79.68% on a YoY basis from $310000.0 in Q1 2024, and down 75.49% quarter-over-quarter from $257000.0 in Q3 2024.
Immunome (IMNM) Current Leases (2019 - 2024) Analysis & Trends
Immunome has reported Current Leases for 3 years, with the latest figure at $63000.0 in Q4 2024.
- For the quarter ending Q4 2024, Current Leases fell 79.68% year-over-year to $63000.0; the trailing twelve-month figure through Dec 2024 stood at $63000.0 (down 79.68% YoY), and the FY2024 full-year result was $63000.0, down 79.68% from the prior year.
- Current Leases for Q4 2024 stood at $63000.0, down from $257000.0 in the prior quarter.
- The five-year high for Current Leases was $310000.0 in Q4 2023, with the low at $63000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 42,980.09 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 83,991.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 7.40 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Immunome | 2.12 Bn | 1.54 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 63,000.00 |
| Sep 30, 2024 | 257,000.00 |
| Dec 31, 2023 | 310,000.00 |
| Dec 31, 2019 | 239,000.00 |